11 research outputs found

    Outpatient satisfaction during pharmacotherapy followup

    Get PDF
    This study aimed to investigate the satisfaction of patients with uncontrolled hypertension referred for pharmacotherapy followup. A cross-sectional study by semi-structured interview was used. The sample comprised patients undergoing pharmacotherapy followup, patients who had discontinued pharmacotherapy followup and patients who had not kept the appointments. A total of 80 (76.9 %) out of 104 patients registered were contacted. The majority of patients undergoing pharmacotherapy followup (91.1 %) were fully satisfied with the pharmacists' care given, their relationship with them (94.9 %), the manner in which their therapy was conducted (99.2 %) and the environment where it was carried out (85.3 %). The reasons for non-attendance were mostly forgetting the date, illness on the appointment day and other arrangements on the same day. Interestingly, all of these patients were completely satisfied with the pharmacists' care given. The satisfaction of patients with the pharmaceutical care is high among patients that have continuous followup, but a relevant proportion discontinued followup. Newer approaches to keep these patients under followup are necessary.Colegio de Farmacéuticos de la Provincia de Buenos Aire

    Outpatient satisfaction during pharmacotherapy followup

    Get PDF
    This study aimed to investigate the satisfaction of patients with uncontrolled hypertension referred for pharmacotherapy followup. A cross-sectional study by semi-structured interview was used. The sample comprised patients undergoing pharmacotherapy followup, patients who had discontinued pharmacotherapy followup and patients who had not kept the appointments. A total of 80 (76.9 %) out of 104 patients registered were contacted. The majority of patients undergoing pharmacotherapy followup (91.1 %) were fully satisfied with the pharmacists' care given, their relationship with them (94.9 %), the manner in which their therapy was conducted (99.2 %) and the environment where it was carried out (85.3 %). The reasons for non-attendance were mostly forgetting the date, illness on the appointment day and other arrangements on the same day. Interestingly, all of these patients were completely satisfied with the pharmacists' care given. The satisfaction of patients with the pharmaceutical care is high among patients that have continuous followup, but a relevant proportion discontinued followup. Newer approaches to keep these patients under followup are necessary.Colegio de Farmacéuticos de la Provincia de Buenos Aire

    Antidepressant-like effect of Valeriana glechomifolia Meyer (Valerianaceae) in mice

    Get PDF
    AbstractThe antidepressant-like effect of a supercritical CO2 (SCCO2) Valeriana glechomifolia extract enriched in valepotriates was investigated in a mice tail suspension test (TST) and forced swimming test (FST). The SCCO2 extract decreased mice immobility in the FST (0.5–20mg/kg p.o.) and elicited a biphasic dose–response relationship in the TST (1–20mg/kg p.o.) with no alterations in locomotor activity and motor coordination (assessed in the open-field and rota-rod tests, respectively). The anti-immobility effect of the SCCO2 extract (5mg/kg, p.o.) was prevented by mice pre-treatment with yohimbine (1mg/kg, i.p., an α2 adrenoceptor antagonist), SCH 23390 (15μg/kg, s.c., D1 dopamine receptor antagonist) and sulpiride (50mg/kg, i.p., D2 dopamine receptor antagonist). However, mice pre-treatments with prazosin (1mg/kg, i.p., α1 adrenoceptor antagonist) and p-chlorophenilalanine methyl ester (4×100mg/kg/day, i.p., a serotonin synthesis inhibitor) were not able to block the anti-immobility effect of the SCCO2 extract. Administration (p.o.) of the SCCO2 extract (0.25mg/kg) and imipramine (10mg/kg), desipramine (5mg/kg) and bupropion (3mg/kg) at sub-effective doses significantly reduced mice immobility time in the FST. These data provide the first evidence of the antidepressant-like activity of V. glechomifolia valepotriates, which is due to an interaction with dopaminergic and noradrenergic neurotransmission

    Uliginosin B, a natural phloroglucinol derivative with antidepressant-like activity, increases Na+,K+-ATPase activity in mice cerebral cortex

    Get PDF
    AbstractUliginosin B, a phloroglucinol isolated from Hypericum polyanthemum Klotzsch ex Reichardt, Hypericaceae, has antidepressant-like effect in the forced swimming test in rodents and inhibits monoamines neuronal reuptake without binding to their neuronal carriers. Studies showed the involvement of Na+,K+-ATPase brain activity in depressive disorders, as well as the dependence of neuronal monoamine transport from Na+ gradient generated by Na+,K+-ATPase. This study aimed at evaluating the effect of uliginosin B on Na+,K+-ATPase activity in mice cerebral cortex and hippocampus (1 and 3h after the last administration) as well as the influence of veratrine, a Na+ channel opener, on the antidepressant-like effect of uliginosin B. Mice were treated (p.o.) with uliginosin B single (10mg/kg) or repeated doses (10mg/kg/day, 3 days). Acute administration reduced the immobility in the forced swimming test and tail suspension test and increased Na+,K+-ATPase activity in cerebral cortex 1h after treating, whereas the repeated treatment induced the antidepressant-like effect and increased the Na+,K+-ATPase activity at both times evaluated. None treatment affected the hippocampus enzyme activity. Veratrine pretreatment prevented uliginosin B antidepressant-like effect in the forced swimming test, suggesting the involvement of Na+ balance regulation on this effect. Altogether, these data indicate that uliginosin B reduces the monoamine uptake by altering Na+ gradient

    Participation of GABA-benzodiazepine Receptor Complex in the Anxiolytic Effect of Passiflora alata Curtis (Passifloraceae)

    No full text
    Passiflora alata Curtis is used in Brazilian folk medicine and also by pharmaceutical industry due to its tranquilizing properties. In this work, the central activity of an aqueous (AQ) and an hydroethanolic (HE) leaves extracts were evaluated in elevated plus maze, barbiturate sleeping time, open field and [3H]flunitrazepam binding assays. The only effect presented by AQ (300 mg/kg, p.o.) was on the barbiturate sleeping time, indicating a hypnotic effect. The HE extract (300 and 600 mg/kg, p.o.) also increased the barbiturate sleeping time and reduced the locomotor activity (at 600 mg/kg, p.o.), pointing to a sedative effect. In addition HE showed an anxiolytic-like effect (300 mg/kg, p.o.) in the elevated plus maze test which was blocked by flumazenil (6 mg/kg, i.p.). Nevertheless HE did not displace [3H]flunitrazepam binding to rat brain synaptosomes in concentrations up to 1000 μg/mL. As a conclusion, we showed that the anxiolytic effect of P. alata in mice depends on the dose and solvent used for the extract preparation, and this effect cannot be attributed to the direct activation of the central benzodiazepine site by the chemical constituents of the extract. It is possible that their metabolites or an indirect effect on benzodiazepine- GABAA receptor complex mediate the observed anxiolytic effect.Colegio de Farmacéuticos de la Provincia de Buenos Aire

    Mucoadhesive Amphiphilic Methacrylic Copolymer-Functionalized Poly(epsilon-caprolactone) Nanocapsules for Nose-to-Brain Delivery of Olanzapine

    No full text
    Nose-to-brain drug delivery has been proposed to overcome the low absorption of drugs in central nervous system due to the absence of brain-blood barrier in the olfactory nerve pathway. However, the presence of a mucus layer and quick clearance limit the use of this route. Herein, amphiphilic methacrylic copolymer-functionalized poly(epsilon-caprolactone) nanocapsules were proposed as a mucoadhesive system to deliver olanzapine after intranasal administration. In vitro evaluations showed that these nanocapsules were able to interact with mucin (up to 17% of increment in particle size and 30% of reduction of particle concentration) and nasal mucosa (2-fold higher force for detaching), as well as to increase the retention of olanzapine (about 40%) on the nasal mucosa after continuous wash. The olanzapine-loaded amphiphilic methacrylic copolymer-functionalized PCL nanocapsules enhanced the amount of drug in the brain of rats (1.5-fold higher compared to the drug solution). In accordance with this finding, this formulation improved the prepulse inhibition impairment induced by apomorphine, which is considered as an operational measure of pre-attentive sensorimotor gating impairment present in schizophrenia. Besides, nanoencapsulated olanzapine did not affect the nasal mucosa integrity after repeated doses. These data evidenced that the designed nanocapsules are a promising mucoadhesive system for nose-to-brain delivery of drugs.Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES
    corecore